Introduction {#Sec1}
============

The American College of Chest Physicians (ACCP) has issued guidelines for the prevention of venous thromboembolism (VTE) since 1986. The 7th and most recent update of these guidelines (ACCP7), published in 2004, are based on a comprehensive assessment of the literature on risk factors and effective thromboprophylaxis regimens \[[@CR1]\]. These guidelines identify specific groups of medical and surgical patients at risk of VTE and provide recommendations for the type (mechanical, pharmacologic, or combination), dose and duration of thromboprophylactic measures. The Joint Commission on Accreditation of Healthcare Organizations and the National Quality Forum have recognized the importance of using thromboprophylaxis to prevent VTE in hospitalized patients \[[@CR2]\]. Moreover, in 2007 two new quality indicators were added to Medicare's Surgical Care Improvement Project: Thromboprophylaxis ordered for surgery patient, and thromboprophylaxis within 24 h pre/post surgery \[[@CR3]\].

Despite the long-standing availability of evidence-based guidelines for thromboprophylaxis, compliance with these in hospitalized patients at risk has remained low. Previous retrospective studies using patient chart reviews have shown that 25 to 84% of hospitalized patients are at risk of VTE and that only 23 to 46% of these patients receive any form of thromboprophylaxis \[[@CR4]--[@CR10]\]. However, assessments of evidence-based thromboprophylaxis are more clinically meaningful when all of the criteria for appropriate thromboprophylaxis are measured. To date, no studies have assessed the appropriateness of thromboprophylaxis against ACCP7 recommendations for the type, dose, and duration of therapy. Assessments using electronic discharge-summary and billing records offer the advantage of including large samples of patients at risk for VTE and the ability to assess not only the rate of thromboprophylaxis but also its appropriateness with respect to type, dose and duration. The primary aim of this project was to support quality improvement efforts at selected US hospitals by measuring implementation of ACCP7 guidelines for type, dose, and duration of thromboprophylaxis across a broad range of medical and surgical conditions.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

The Venous Thromboembolism Study to Assess the Rate of Thromboprophylaxis (VTE START) was part of a quality improvement initiative designed to help hospitals assess and improve their use of appropriate thromboprophylaxis. A Steering Committee of researchers and clinical experts in thromboprophylaxis were responsible for the design and implementation of the project. Participation was offered by the Steering Committee to a convenience sample of acute-care hospitals of various sizes in urban and rural areas of the Midwest and Southwest. Of 16 that participated, 13 hospitals were affiliated with a single health system, and two hospitals had implemented some type of a prophylaxis program during the 2005--2006 period. Participating hospitals provided electronic patient-level discharge-summary and billing records for 2005--2006. Discharge-summary records contained demographic data (age, gender, race), admission and discharge dates, referral source and type of insurance. Primary and secondary codes for diagnoses and procedures (in International Classifications of Diseases, 9th revision, Clinical Modification \[ICD-9-CM\] format) and specialty of the attending or admitting physician were also available. Billing records provided daily information on inpatient services provided and pharmacy data describing medication type, quantity, and dose. Hospital-level data included bed count and indicators for teaching or non-teaching, rural or urban, and for-profit or non-profit.

All patient records were de-identified by the hospitals in compliance with the Privacy Rule of the Health Insurance Portability and Accountability Act of 1996 \[[@CR13]\]. The study protocol was approved or exempted by the Institutional Review Board governing each participating institution. After the study, participating hospitals were provided the pooled results for all 16 hospitals as well as the results specific to their institution for purposes of comparison and use in their quality improvement initiatives.

Study population {#Sec4}
----------------

Patients 18 years and older at admission, who had an inpatient stay ≥2 days between January 1, 2005 and December 31, 2006, were eligible for inclusion. Patients meeting one or more of the following were excluded from the analyses: (1) transferred from another acute-care facility where they may have already received thromboprophylaxis; (2) pregnancy-related discharge diagnosis owing to precautions for anticoagulant use in pregnant women; (3) other conditions where thromboprophylaxis could be contraindicated were also excluded based on ICD-9-CM diagnosis and procedure codes for active bleeding or indicating a potentially high risk of bleeding due to certain liver diseases, malignant hypertension, certain blood diseases, active peptic ulcer and renal dysfunction; and (4) discharge diagnosis of VTE in order to distinguish between VTE prophylaxis and treatment.

Patients at risk {#Sec5}
----------------

Patients were grouped into potentially at-risk cohorts based on ACCP7 guidelines. We created mutually exclusive groups of critical care, surgical, and medical patients based on hospital discharge-summary and billing records. For example a patient was flagged as critical care if he/she had a billing code indicative of time he/she spent in critical care unit. Surgical and medical patients were identified using ICD9-CM diagnosis and procedure codes indicative of the surgery and condition of interest (see Table [1](#Tab1){ref-type="table"}, technical appendix). Patients were placed in the most severe group for which they qualified (critical care being the highest in severity and medical conditions being the lowest) For instance a trauma patient who required surgery was classified as surgery. Next, they were subclassified into seven mutually exclusive diagnostic groups adapted from ACCP7 (see Table [1](#Tab1){ref-type="table"}) \[[@CR1]\]. Surgical procedures were classified as non-major (operations other than abdominal lasting \<45 min) or major (any intra-abdominal operation and any other operations lasting ≥45 min) \[[@CR14]\]. Low, moderate and high levels of surgical risk were defined based on ACCP7 risk factors \[[@CR1]\]. The final determination of at-risk status and recommended thromboprophylaxis was based on assessments of "additional risk factors" as specified in ACCP7 \[[@CR1]\]. Risk factors were identified using relevant ICD9-CM diagnoses and procedure codes. Risk factors such as smoking and immobility that are difficult to determine using ICD9-CM codes were not captured.Table 1Characteristics of patients at risk of VTE in 2005--2006, by major diagnostic group (*n* = 68,278)Patient characteristicsCritical careSurgeryMedicalTotalGeneral, vascular, gynecologic, laparoscopic, and urologicOrthopedicNeurosurgeryTotal surgeryTrauma, spinal cord, injuries, and, burnsGeneral medical^†^CancerTotal medicalNumber of patients at risk of VTE21,08115,7837,7761,18324,7421,72019,0111,72422,45568,278    Age, %      18--3910.218.73.311.213.518.50.01.01.58.5      40--4912.121.68.410.116.913.511.86.911.613.7      50--5918.620.220.614.920.116.815.515.015.518.1      60--6920.716.226.223.119.713.218.624.018.619.7      70+38.323.341.640.829.938.054.153.025.840.0    Race, %      Caucasian81.877.088.580.680.885.184.287.984.682.3      African American7.710.23.64.67.93.87.36.16.97.5      Asian0.91.10.40.70.80.80.80.60.80.8      Hispanic6.89.24.611.77.98.75.33.85.56.8      Other0.80.90.70.90.80.20.50.30.40.7      Not documented2.01.62.21.51.81.41.91.21.81.9Gender, %      Male51.135.836.850.936.841.040.145.140.642.5      Female48.964.263.249.163.259.059.954.959.457.5      Not documented0.00.00.00.00.00.00.00.00.00.0    Length of staty, days(SD)6.3 (6.4)5.3 (5.2)4.3 (2.5)4.6 (5.2)5.0 (4.5)5.6 (4.8)4.5 (2.9)6.1 (4.4)4.7 (3.3)5.3 (4.9)    Referral source, %      Physician61.656.258.365.357.369.756.956.757.958.8      ER35.242.941.233.641.928.442.042.141.039.5      Other3.10.90.61.00.81.91.01.21.11.6      Not documented0.00.00.00.10.00.00.00.00.00.0    Primary attending physician specialty^‡^, %      Cardiology22.91.70.10.31.10.26.84.66.19.5      Internal medicine and primary care43.624.07.44.317.926.776.555.771.143.3      Neurology8.60.96.154.15.01.60.70.20.84.7      Oncology0.73.00.10.51.90.10.118.31.51.4      Orthopedic1.91.672.814.024.534.40.61.33.310.6      Surgery9.437.60.83.624.428.01.13.13.312.8      Other9.428.210.222.422.34.17.110.37.113.3      Not documented3.73.12.50.82.84.87.06.66.84.4    Payer type, %      Public^§^48.432.548.147.338.144.063.862.862.249.2      Commercial43.759.349.146.355.539.630.934.631.944.1      No insurance7.27.00.81.74.810.94.82.25.15.6      Other0.00.00.00.00.00.00.00.00.00.0      Not documented0.81.12.04.61.65.50.50.40.91.1    Number of additional VTE risk factors\*\*, %      No risk factors12.224.051.265.134.50.344.20.037.528.6      1 or more risk factors87.876.048.834.965.599.755.8100.062.571.4      1 risk factor34.441.536.625.339.271.641.41.040.638.2      2+ risk factors53.434.512.29.626.328.114.499.021.933.2Classifications and risk factors are adapted from the 7th ACCP Guidelines \[[@CR1]\]^†^General medical includes heart failure, severe respiratory disease, acute myocardial infarction, stroke, and severe infectious disease^‡^Cardiology: cardiology, cardiovascular disease, or cardiology/electrophysiology; internal medicine and primary care: family practice, family nurse practitioner, general practice, hospitalist, or internal medicine; oncology: oncology or radiation oncology; surgery: cardiothoracic surgery, general surgery, neurosurgery, plastic and reconstructive surgery, or unspecified surgical specialty; orthopedic: orthopedic or orthopedic surgery; other: adult nurse practitioner, anesthesiology, critical care, dentist, dermatology, emergency medicine, family nurse practitioner, gastroenterology, hematology, nephrology, ophthalmology, pathology, physical medicine/rehabilitation, physician assistant, podiatry, pulmonary, rheumatology, urology, pediatric medicine, radiology, or ear/nose/throat; not documented: could not be determined from the data due to missing values^§^Public payers include medicare, medicaid, veteran's health, and Indian health service\*\* Defined as any additional risk factors beyond the actual diagnostic groups. Risk factors were determined using primary and secondary diagnosis and procedure codes. In addition to the risk factors defined by each of the seven diagnostic groups, 71.4% of at-risk patients had at least one additional risk factor for VTE and 33.2% had two or more risk factors. The top three risk factors for all patients were heart/respiratory failure (34.7%), acute medical illness (25.7%) and surgery (17.3%)

Study measures {#Sec6}
--------------

The primary endpoint was the rate of appropriate thromboprophylaxis. This assessment was based upon ACCP7 recommendations for each cohort of patients at risk. Appropriate thromboprophylaxis rates were determined using four criteria: (1) whether the patient received any thromboprophylaxis; (2) whether the appropriate type of thromboprophylaxis (mechanical or pharmacologic) was used; (3) whether the pharmacologic regimen (if any) was given at a dose greater or equal to the minimum recommended daily dose; and (4) whether the regimen was administered for greater or equal to the recommended number of days. ACCP7 recommends thromboprophylaxis for the length of stay (LOS) for patients at risk of VTE. However, for medical patients, duration was considered sufficient in this study if thromboprophylaxis was received for LOS minus 1 day to accommodate partial days of stay. For surgical patients, duration of LOS minus 2 days was considered sufficient to accommodate partial days of stay and procedures for which thromboprophylaxis is not recommended on the day of surgery. Duration of prophylaxis for pharmacologic agents was calculated by summing up the number days for which a relevant billing code was recorded. For mechanical prophylaxis, duration was calculated as the total number of days between the first billing date during which a relevant billing code was recorded and the discharge date. The rate of appropriate thromboprophylaxis was calculated as the total number of appropriately treated patients divided by the number of patients at risk of VTE. Appropriate thromboprophylaxis rates were determined for the full study period and for each calendar quarter, as well as by primary attending physician specialty, hospital characteristics and LOS.

The study's secondary endpoint was the proportion of all hospitalized patients at risk of VTE. This was calculated as the total number of patients at risk divided by the total number of discharged patients.

Results {#Sec7}
=======

Patient population and characteristics {#Sec8}
--------------------------------------

Of 258,556 patients for whom data were available, 135,954 (53%) met at least one exclusion criterion (Fig. [1](#Fig1){ref-type="fig"}). After establishing the main diagnostic groups (critical care, surgical, and medical) and applying the additional risk-factor criteria specified in ACCP7, we identified 68,278 patients at risk of VTE (26.4%). Of these, approximately equal percentages were critical care, surgical, and medical patients. Most patients were female, elderly, and Caucasian with an average LOS of 5.3 days, attended by internists and primary care physicians, and insured by public (mostly Medicare and Medicaid) or commercial health insurance (Table [1](#Tab1){ref-type="table"}).Fig. 1Construction of study sample

Rate of appropriate thromboprophylaxis {#Sec9}
--------------------------------------

A total of 43,125 patients, or 63.2% of those at risk of VTE, received some type of mechanical or pharmacologic thromboprophylaxis (Table [2](#Tab2){ref-type="table"}). This rate was greatest for critical care patients, followed by surgical then medical. However, only 12.9% of at-risk patients received appropriate type and dose and duration based on ACCP7 criteria (20.4% of those receiving any thromboprophylaxis). The rate of appropriate thromboprophylaxis was highest for surgical patients, followed by critical care and medical patients (17.9, 10.5, and 9.8%, respectively). Among documented physician specialties, the rate of appropriate thromboprophylaxis was highest for orthopedics followed by cardiology (32.0 and 18.3%, respectively), but still poor overall. Across all categories, 87.1% of at-risk patients received either no thromboprophylaxis or inappropriate thromboprophylaxis.Table 2Rates of any and appropriate VTE prophylaxis among patients at risk of VTE (*n* = 68,278)N at riskReceived any prophylaxisReceived no prophylaxisReceived appropriate type, dose, and duration of prophylaxis, % of total at riskReason for inappropriate prophylaxis, percent of N at riskN%N%Inappropriate typeAppropriate type and dose but in sufficient durationAppropriate type and duration but in appropriate doseAppropriate type inappropriate dose insufficient durationCritical care21,08115,72674.65,35525.410.535.74.113.910.5Surgery24,74216,41066.38,33233.717.917.13.07.321.0    General, vascular, gynecologic and urologic surgery      General8,9225,20358.33,71941.77.512.22.68.927.1      Major vascular surgery2,8602,020,70.684029.49.116.511.529.34.2      Major gynecologic2,6691,26947.51,40052.57.51.13.90.334.7      Laparoscopic surgery37825968.511931.541.85.35.05.610.8      Major urologic95454056.641443.431.63.91.72.816.7    Orthopedic surgery      Elective hip arthroplasty2,1061,85688.125011.937.538.60.20.011.8      Elective knee arthroplasty3,7463,31388.443311.640.233.60.40.114.2      Knee arthroscopy11100.000.00.0100.00.00.00.0      Hip fracture surgery81463778.317721.717.145.91.24.49.6      Elective spine surgery1,10970063.140936.931.09.81.43.117.8    Neurosurgery1,18361251.757148.35.22.70.83.339.6    Risk level     Low8450.0450.00.00.00.00.05.7     Moderate3,9102,07653.11,83446.914.79.86.415.56.5     High20,82414,33068.86,49431.218.518.52.45.723.7Medical Conditions22,45510,98948.911,46651.19.824.71.14.29.2    Trauma, spinal cord injury, burns      Trauma1,7001,02760.467339.638.216.50.00.05.7      Acute spinal cord injuries13646.2753.80.00.00.023.123.1      Burns7342.9457.10.042.90.00.00.0    General medical      Heart failure2,7381,62659.41,11240.69.829.70.53.116.3      Severe respiratory disease5,2572,40645.82,85154.27.326.60.62.98.3      Acute myocardial infarction86472784.113715.927.832.811.510.41.7      Stroke1,65486352.279147.87.031.30.71.411.8      Severe infectious disease8,4983,43040.45,06859.65.422.10.63.78.6    Cancer1,72490152.382347.74.422.22.015.58.1Primary attending physician specialty\*    Cardiology6,4805,76989.071111.018.347.96.611.74.6    Internal medicine and primary care29,56616,57356.112,99343.97.728.11.98.69.8    Neurology3,2261,92259.61,30440.48.213.62.79.825.2    Oncology97070672.826427.27.312.33.622.127.5    Orthopedic7,2056,04283.91,16316.132.034.10.81.415.5    Surgery8,7556,10069.72,65530.313.415.94.212.323.9    Other9,0935,09956.13,99443.914.114.13.06.518.4    Not documented2,98391430.62,06969.49.37.41.42.110.4Total68,27843,12563.225,15336.812.925.42.78.313.9\*Cardiology: cardiology, cardiovascular disease, or cardiology/electrophysiology; internal medicine and primary care: family practice, family nurse practitioner, general practice, hospitalist, or internal medicine; oncology: oncology or radiation oncology; surgery: cardiothoracic surgery, general surgery, neurosurgery, plastic and reconstructive surgery, or unspecified surgical specialty; orthopedic: orthopedic or orthopedic surgery; other: adult nurse practitioner, anesthesiology, critical care, dentist, dermatology, emergency medicine, family nurse practitioner, gastroenterology, hematology, nephrology, ophthalmology, pathology, physical medicine/rehabilitation, physician assistant, podiatry, pulmonary, rheumatology, urology, pediatric medicine, radiology, or ear/nose/throat; not documented: could not be determined from the data due to missing values

The leading reason for failure to meet ACCP7 criteria (Table [2](#Tab2){ref-type="table"}) was no thromboprophylaxis at all (36.8% of at-risk patients). Additionally, patients frequently received thromboprophylaxis regimens that were of the inappropriate type (25.4% of at-risk patients); appropriate type but inadequate dose and insufficient duration (13.9%); appropriate type and sufficient duration but inadequate dose (8.3%); and appropriate type and adequate dose but insufficient duration (2.7%). Of patients who received any thromboprophylaxis, 25.3% received it on only 1 day, 16.1% on 2 days and 15.2% on 3 days; it was most often initiated on the first day of the stay (67.4%).

Over the 2-year study period, the overall (critical care, surgery and medical conditions combined) quarterly rates of appropriate thromboprophylaxis reflected modest improvement, from 11.6% in the first quarter of 2005 to 14.5% in the last quarter of 2006. However the rate of improvement over time varied across the individual cohorts (Fig. [2](#Fig2){ref-type="fig"}). The rate of appropriate thromboprophylaxis varied according to hospital characteristics. Higher rates of appropriate thromboprophylaxis were observed for large hospitals compared to small hospitals (Table [3](#Tab3){ref-type="table"}). Patients were also more likely to receive thromboprophylaxis based on ACCP7 in urban, teaching, and for-profit hospitals.Fig. 2Patients at risk of VTE who received appropriate prophylaxis by diagnostic group over time (*n* = 68,278)Table 3Rates of any and appropriate VTE prophylaxis among patients at risk of VTE, by hospital characteristics (*n* = 68,278)Hospital characteristicTotal at risk, NReceived any prophylaxisReceived no prophylaxisReceived appropriate type, dose, and duration of prophylaxis % of N at riskReason for inappropriate prophylaxis, percent of N at riskN%N%Inappropriate typeAppropriate type and dose but insufficient durationAppropriate type and duration but inappropriate doseAppropriate type but insufficient durationNumber of beds      0--1005,5672,82550.72,74249.311.924.91.04.98.0      101--50036,95721,24257.515,71542.511.322.12.96.714.5      501--100025,75419,05874.06,69626.015.430.22.811.414.2      1000+----0.00.00.00.00.00.00.0Geographic location      Urban59,74039,52366.220,21733.813.626.03.09.214.3      Rural8,5383,60242.24,93657.88.420.70.51.910.6Teaching status      Teaching10,7916,19157.44,60042.615.619.12.13.017.6      Non-Teaching57,48736,93464.220,55335.812.426.52.89.313.2Type      Not-for-profit57,48736,93464.220,55335.812.426.52.89.313.2      For-profit10,7916,19157.44,60042.615.619.12.13.017.6Payer mix      Public33,60120,50761.013,09439.010.327.71.87.713.5      Commercial30,08819,82665.910,26234.115.523.13.78.814.8      Other4,5892,79260.81,79739.215.622.82.89.310.4

Discussion {#Sec10}
==========

This study demonstrates that the 7th ACCP guidelines for type, dose and duration of thromboprophylaxis were not implemented to a high degree in participating hospitals. While nearly two-thirds of patients at risk of VTE received some form of thromboprophylaxis, fewer than one in seven (or about one in five of those who received any thromboprophylaxis) received the appropriate type, dose and duration. The proportions of patients receiving appropriate thromboprophylaxis were alarmingly low for every diagnostic group, physician specialty, hospital category, and time period studied.

Hospitals may have intended to implement ACCP7 to varying degrees, and this may partially explain the low levels of appropriate thromboprophylaxis observed in our study. However, the use of alternative guidelines or standards for thromboprophylaxis is unlikely to explain the absence of any thromboprophylaxis in 37% of at-risk patients. Indeed, the high rate of omission of any form of thromboprophylaxis in medical and surgical patients found in this study is consistent with the findings of other studies \[[@CR5], [@CR11], [@CR12], [@CR16]\]. In those patients who did get thromboprophylaxis, the regimen did not reflect ACCP7 guidelines nearly 80% of the time, and the leading cause was inappropriate type (e.g., giving mechanical only when pharmacologic was indicated). Thus, our findings demonstrate a persistent and worrisome gap in the performance of evidence-based thromboprophylaxis for hospitalized patients at participating institutions.

VTE START is, to our knowledge, the only study that has assessed the appropriateness of thromboprophylaxis in multiple US hospitals using the 7th ACCP guidelines for type, dose, and duration. Previous retrospective studies using patient chart reviews have shown that 25 to 84% of hospitalized patients are at risk of VTE and that only 23 to 46% of these patients receive any form of thromboprophylaxis \[[@CR4]--[@CR8]\]. However, these studies were based on relatively small samples of patients (range: 100--4124) with medical conditions and relied on the 6th ACCP or non-ACCP guidelines. Two recent, large international registries, using chart review, assessed the use of thromboprophylaxis against ACCP7 \[[@CR9], [@CR10]\]. However, the ENDORSE study of 68,183 patients in 32 countries \[[@CR9]\] did not include duration of thromboprophylaxis, and the IMPROVE study of 15,156 patients in 12 countries \[[@CR10]\] did not assess the appropriateness of the type of the thromboprophylaxis received. Two other recent studies \[[@CR11], [@CR12]\] used electronic databases of patient records to assess the appropriateness of thromboprophylaxis against the 6th rather than the 7th ACCP guidelines. Yu and colleagues \[[@CR11]\] reported appropriate thromboprophylaxis in only 13.3% of patients across a similar range of diagnostic groups. Amin and colleagues \[[@CR12]\] found the rate of appropriate thromboprophylaxis to be 33.9% among high-risk medical patients. It is worth noting that there is no significant difference between the 6th and the 7th ACCP guidelines in terms of the criteria for appropriate prophylaxis, therefore the bases of the results from our study should be comparable to the bases of the results obtained from those published studies.

Our results should be interpreted in light of several limitations. First, we employed discharge-summary and billing data to assess risk status and appropriateness of thromboprophylaxis. While such electronic data allow for rapid and efficient analysis of all patients in an institution, there is the possibility of measurement error because certain risk factors cannot be fully assessed based on discharge and billing records. This may have led to inaccurate assumptions about a patient's at-risk status or appropriate thromboprophylaxis regimen. For example, we determined that 26% of all hospitalized patients were at risk of VTE and had no apparent contraindications for thromboprophylaxis. These results are similar to other studies using hospital discharge-summary and billing data (13--31%)\[[@CR11], [@CR15]\] but at the lower end of the range of results from chart-based evaluations (25--84%)\[[@CR4]--[@CR8], [@CR16]\]. This may be due to our large sample representing more categories of patients than previous studies, but it may also reflect our liberal exclusion criteria for potential bleeding risk, which increased the number of patients for whom thromboprophylaxis was contraindicated and reduced the proportion at risk of VTE. Our approach is consistent with previous studies using discharge-summary and billing data\[[@CR11], [@CR12]\], and reflects a desire to under-estimate rather than over-estimate the proportion of patients at risk of VTE. With this in mind, it is worth noting that we had no access to patients' clinical history such as recent (\<30 days) GI bleeding, therefore we might have been overestimated the at risk population as described herein. Similarly, we may have overestimated the number of patients receiving appropriate thromboprophylaxis because we imposed no upper bound on dose and a low threshold for appropriate duration. Both of these criteria reflect our intent to be as liberal as possible where there was uncertainty in our ability to determine appropriate thromboprophylaxis. Finally, our small sample of 16 hospitals was not intended to be nationally representative, and the fact that 13 of them were part of a single hospital system may have reduced the variance within the sample. Further, the observed variation in the rate of prophylaxis across the participating hospitals are likely to be confounded due the fact that some of these hospitals had some initiative in place for improving prophylaxis. The extent to which the low levels of thromboprophylaxis found in these hospitals reflect the levels in other US hospitals is unknown.

Our results demonstrate an alarmingly low degree of implementation of the 7th ACCP guidelines and imply the need for urgent action by physicians and health systems to assess risk and deliver appropriate thromboprophylaxis. Interventions in the form of educational programs, risk stratification, critical pathways and alert tools have been effective in increasing the rate of thromboprophylaxis \[[@CR8], [@CR11], [@CR17]--[@CR19]\]. An additional strength of this project was the delivery of benchmarking reports to participating hospitals, for use in the development and evaluation of their own quality improvement initiatives. Institutions may find that analyzing their administrative databases on all patients is a more efficient and comprehensive method than manual chart abstraction of small samples of patients for assessing thromboprophylaxis rates and the impact of quality improvement initiatives.

Conclusions {#Sec11}
===========

This study demonstrates the significant gap between evidence-based thromboprophylaxis recommendations and actual clinical practice in a large sample of hospitalized patients. More than 25% of hospitalized patients were at risk of VTE, but fewer than one in seven of these patients received thromboprophylaxis that met criteria for recommended type, dose and duration. We recommend intensive efforts to improve the degree of implementation of current guidelines for appropriate thromboprophylaxis.
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Appendix {#Sec12}
========

See Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}.Table 4Criteria for determining appropriate prophylaxis by study cohortStudy cohortAdditional stratificationAppropriate prophylaxis*Critical care*Critical care• All patients*Type*: LDUH or LMWH• Major trauma or orthopedic surgeryDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1 (medical) LOS-2 (surgical)*Type*: LMWHDose: See minimum prophylaxis dosein Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS -1 (trauma) LOS-2 (orthopedic surgery)*General, transplant, vascular, gynecologic, urologic, laparoscopic surgery*General• Non-major surgery, age less than 40, additional risk factors, or*Type*: LDUH, LMWH, GCS or IPCDose: LDUH (10,000 units/day); LMWH (≤3,400 IU/day)• Non-major surgery, age 40--60, regardless of risk factors, orDuration: LOS-2• Major surgery, age less than 40, regardless of risk factors• Non-major surgery, age 60 or older, and with or without risk factors, or*Type*: LDUH, LMWHDose: LDUH (15,000 units/day), LMWH (\>3,400 IU/day)• Major surgery, greater than 60 years of age, and with no risk factors, orDuration: LOS-2• Major surgery in patients \<40, additional risk factors, or• Major surgery in patients between the ages of 40--60• Major surgery with greater than 60 years of age with additional risk factors*Type*: LDUH + (GCS or IPC), or LMWH + (GCS or IPC)Dose: LDUH (15,000 units/day), LMWH (\>3,400 IU/day)Duration: LOS-2Transplant*Note*: This is part of general surgery and will be treated as suchSame as general surgeryVascularNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2Gynecologic• Major GYN surgery (benign disease) and no additional risk factors*Type*: LDUH, LMWH, or IPCDose: LDUH (10,000 units/day) LMWH(≤3,400 IU/day)Duration: LOS-2• Major GYN surgery with malignant GYN neoplasms, regardless of risk factors*Type*: LDUH, LMWH, IPC or LDUH/LMWH with GCS/IPCDose: LDUH 15,000 units/day) LMWH (\>3,400 IU/day)• Major GYN surgery(benign disease) and additional risk factorsDuration: LOS-2• Laproscopic GYN procedures with additional risk factors*Type*: LDUH, LMWH, IPC, or GCSDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2Urologic• One or no risk factors*Type*: LDUH or GCS or IPCDose: LDUH (10,000 units/day)Duration: LOS-2• Two or more risk factors*Type*: LDUH + GCS or IPC, LMWH + GCS or IPCDose: LDUH (10,000 units/day), LMWH (See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.)Duration: LOS-2LaparoscopicNone*Type*: LDUH, LMWH, GCS, IPCDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2Orthopedic SurgeryElective hip arthroplastyNone*Type*: LMWH, fondaparinux or VKADose: LMWH (\>3,400 IU/day), Fondaparinux (2.5 mg/day), VKA (regardless of the dose)Duration: LOS-2Elective knee arthroplastyNone*Type*: LMWH, Fondaparinux or VKADose: LMWH (\>3,400 IU/day), Fondaparinux (2.5 mg/day), VKA (regardless of the dose)Duration: LOS-2Knee arthroscopyNone*Type*: LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2Hip fracture surgery*Type*: LMWH, fondaparinux, VKA, LDUHDose: LMWH(\>3,400/day) Fodaparinux (2.5 mg/day) VKA (regardless of dose) LDUH (10,000 units/day)Duration: LOS-2Elective spine surgery• One or no additional risk factors*Type*: LDUH, LMWH, IPC, or GCSDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2• Two or more risk factors*Type*: LDUH + (any GCS or IPC), LMWH + (any GCS or IPC)Dose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2*Neurosurgery*Neurosurgery• Age less than 40 with additional risk factor*Type*: LMWH, UFH, IPC or GCSDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2• Age 40 or above regardless of risk factors*Type*: LMWH + (IPC or GCS), or UFH + (IPC or GCS)Dose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-2*Trauma, spinal cord injuries, burns*TraumaNone*Type*: LMWH, GCS or IPCDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1Spinal cord injuriesNone*Type*: LMWH, LMWH + IPC, or LDUH + IPCDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1BurnsNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1*Acutely Ill medical patients*Heart failureNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1Severe respiratory infectionNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1Acute myocardial infractionNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1StrokeNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1Severe infectious diseaseNone*Type*: LDUH or LMWHDose: See minimum prophylaxis dose in Table [5](#Tab5){ref-type="table"}, technical appendix.Duration: LOS-1CancerWithout surgery (medical conditions)Assessed according to the accompanying medical conditionTable 5Label based dosing for pharmacologic prophylaxis and the minimum dose per day utilized in the studyDrugsLabel prophylaxis dosing regimenMinimum (per day)*Fondaparinux*Fondaparinux (Arixtra^®^)---THR, TKR, HFS, abdominal surgery2.5 mg SQ QD2.5 mg*UFH*Heparin5,000 USP units SQ 2--3 times per day; 7,500 USP units SQ 2 times per day10,000 IU SQ*LMWH*Tinzaparin (Innohep^®^)75 units/kg4,500 IU\*Dalteparin (Fragmin^®^)---THR, abdominal surgery, medically ill2,500--5,000 anti-Xa IU SQ QD2,500 IUEnoxaparin (Lovenox^®^)---THR, TKR, abdominal surgery, medically ill30 mg SQ BID or 40 mg QD (obese patient = 40 mg BID; renal dosing = 30 mg QD)30 mg (3,000 IU)VKAWarfarin2--10 mg PO QD adjusted to INR = 2--32 mg\*Assuming an average body weight of 60 KGBID: twice daily; *HFS* hip fracture surgery; *INR* international normalized ratio; *IU* international units; *SQ* subcutaneous; *QD* once daily; *THR* total hip replacement; *TKR* total knee replacementSources: Package labeling; Nutescu EA, Wittkowsky AK, Dobesh PP, Hawkins DW, Dager WE. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach. *Ann Pharmacother* 2006 Sep;40(9):1558-71. Epub 2006 Aug 15

ACCP

:   American college of chest physicians

ACCP7

:   American college of chest physicians 7th and most recent guidelines

ENDORSE

:   Epidemiologic international day for the evaluation of patients at risk for venous thromboembolism in the acute hospital care setting

ICD-9-CM

:   International classifications of diseases, 9th revision, clinical modification

IMPROVE

:   International medical prevention registry on venous thromboembolism

LOS

:   Length of stay

VTE

:   Venous thromboembolism

VTE START

:   Venous thromboembolism study to assess the rate of thromboprophylaxis
